Free Trial

AlloVir Q3 2024 Earnings Report

AlloVir logo
$0.45 +0.00 (+0.91%)
As of 01/3/2025 05:38 PM Eastern

AlloVir EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

AlloVir Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AlloVir Announcement Details

Quarter
Q3 2024
Time
N/A

Conference Call Resources

AlloVir Earnings Headlines

AlloVir, Inc. (NASDAQ:ALVR) Short Interest Down 12.0% in December
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
AlloVir Appoints Vikas Sinha as New CEO
See More AlloVir Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AlloVir? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AlloVir and other key companies, straight to your email.

About AlloVir

AlloVir (NASDAQ:ALVR), a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

View AlloVir Profile

More Earnings Resources from MarketBeat